Organization: Centre of Excellence for Commercialization and Research

Innovation Conversations: Q&A with CDRD president and CEO Gordon C. McCauley

Vancouver-based Centre for Drug Research and Development (CDRD) is an 11-year-old organization that helps “bridge” scientific discoveries and commercialization in the life sciences sector. RE$EARCH MONEY spoke to CDRD president and CEO Gordon C. McCauley about how it is helping companies scale up and its strategy for attracting capital in a sector that is growing exponentially but is perceived to be risky.

Justin Leushner

Justin Leushner has been appointed CEO of the Centre for Imaging Technology Commercialization (CIMTEC)…

Fusion raises US $25 million for cancer targeting technology

Fusion Pharmaceuticals Inc, a spin out of the Centre for Probe Development and Commercialization (CPDC), has secured US$25 million in series ‘A’ financing to support and accelerate development of new next-generation therapeutics that precisely target cancer cells.

UBC and partners sign major licensing deal with Roche

The Univ of British Columbia has completed its largest licensing agreement to date for a promising treatment for advanced prostate cancer. The agreement with Roche, a Basel, Switzerland-based multinational, was signed by UBC and the Vancouver Coastal Health Research Institute which co-host the Vancouver Prostate Centre where the new drug technology was developed and is…

Six neuroscience teams awarded $8.5 million

CQDM (a Centre of Excellence for Commercialization and Research), Brain Canada and the Ontario Brain Institute have awarded nearly $8.5 million — augmented by $1.5 million in in-kind contributions — to six multi-provincial research teams. The investment will see 33 researchers from academia partnering with smaller companies to develop tools, technologies and platforms that accelerate…

Wavefront receives $9.5 million in CAIP support

Wavefront will expand its reach and programs for wireless innovation across the country with $9.5 million in funding from the Canada Accelerator and Incubator Program (CAIP). Wavefront works with mobile and Internet of Things entrepreneurs by providing services and mentorship to develop products, establish markets and expand their businesses. The Vancouver-based Centre of Excellence for…

Wavefront releases first impact assessment

Wavefront, a Centre of Excellence for Commercialization and Research (CECR), has released its first economic impact assessment demonstrating that it accelerates time-to-market by four-to-six months and saved participating wireless companies $2.2 million through its suite of business assistance services. The Vancouver-based organization also found that it generated $4.80 in economic benefits for every dollar received.…

Wavefront signs agreements with Deutsche Telekom & HP

Vancouver-based Wavefront has entered a long-term agreement with Deutsche Telekom which will see the German telecommunications giant provide access to its machine-to-machine (M2M) resources for use by small and early-stage wireless firms seeking to accelerate their product and services into the marketplace. Wavefront – a Centre of Excellence for Commercialization and Research – recently opened…

Wavefront launches M2M accelerator service

Wavefront, a Centre of Excellence for Commercialization and Research focused on the wireless sector, has launched an accelerator program aimed at the rapidly growing field of machine-to-machine companies and technologies. The M2M Accelerator Program — in conjunction with Rogers and Sierra Wireless — provides services for prototyping and product launch. Its offerings include development hardware…

Amorfix teams with PREVENT for vaccine candidates

Toronto’s Amorfix Life Sciences Ltd has granted exclusive worldwide rights for the commercialization of its lead amyotrophic lateral sclerosis (ALS) vaccines to Pan-Provincial Vaccine Enterprise Inc (PREVENT). PREVENT — a Centre of Excellence for Commercialization and Research (CECR) — will take over clinical development of Amorfix’s lead vaccine candidates for ALS. The cost-sharing, revenue-sharing agreement…